References
- Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold. JAMA. 2020;323(8):707. [published online ahead of print, 2020 Jan 23]. doi:https://doi.org/10.1001/jama.2020.0757.
- de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nature Rev Microbiol. 2016;14(8):523. doi:https://doi.org/10.1038/nrmicro.2016.81.
- Malik YS, Sircar S, Bhat S, Khan S, Dhama K, Dadar M, Tiwari R, Chaicumpa W. Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Quart. 2020a;40(1):68–76. doi:https://doi.org/10.1080/01652176.2020.1727993.
- Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana K, Morales AJR. Coronavirus disease 2019–COVID-19. Preprints. 2020b:2020030001. doi:https://doi.org/10.20944/preprints202003.0001.v2.
- WHO Coronavirus disease (COVID-19) Situation Report No. 201 ( As on 8th August 2020). [accessed 2020 Aug 9]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200808-covid-19-sitrep-201.pdf?sfvrsn=121bb855_2
- Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020;dyaa033. [published online ahead of print, 2020 Feb 22]. doi:https://doi.org/10.1093/ije/dyaa033.
- Malik YS, Sircar S, Bhat S, Vinodhkumar OR, Tiwari R, Sah R, Rabaan AA, Morales AJR, Dhama K. Emerging coronavirus disease (COVID-19), a pandemic public health emergency with animal linkages: current status update. Preprints. 2020b:2020030343. doi:https://doi.org/10.20944/preprints202003.0343.v1.
- Chan JF, Yuan S, Kok K-H, To KKW, Chu H, Yang J, Xing F, Liu J, Yip CCY, Poon RWS, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23. doi:https://doi.org/10.1016/S0140-6736(20)30154-9.
- Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–79. doi:https://doi.org/10.1056/NEJMc2001737.
- Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng O-T, Marimuthu K, Ang LW, Mak TM, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488–94. [published online ahead of print, 2020 Mar 3] [published correction appears in JAMA. doi: https://doi.org/10.1001/jama.2020.4372]. doi:https://doi.org/10.1001/jama.2020.3204.
- Peiris JS, Yuen KY, Osterhaus AD, Stöhr K. The severe acute respiratory syndrome. N Engl J Med. 2003;349(25):2431–41. doi:https://doi.org/10.1056/NEJMra032498.
- Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020;1–7. [published online ahead of print, 2020 Mar 18]. doi:https://doi.org/10.1080/21645515.2020.1735227.
- Zhang YZ, Holmes EC. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell. 2020;181(2):223–27. doi:https://doi.org/10.1016/j.cell.2020.03.035.
- Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16(10):1753–66. Published 2020 Mar 15. doi:https://doi.org/10.7150/ijbs.45134.
- Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. Clin Therapeut. 2013;35(2):109–14. doi:https://doi.org/10.1016/j.clinthera.2013.01.007.
- Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473–78. doi:https://doi.org/10.1016/j.cmi.2019.04.020.
- Kleinnijenhuis J, Quintin J, Preijers F, Joosten LAB, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, et al. Bacille calmette-guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA. 2012;109(43):17537–42. doi:https://doi.org/10.1073/pnas.1202870109.
- Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12(4):E372. Published 2020 Mar 27. doi:https://doi.org/10.3390/v12040372.
- Ayoub BM. COVID-19 vaccination clinical trials should consider multiple doses of BCG. Pharmazie. 2020;75(4):159. doi:https://doi.org/10.1691/ph.2020.0444.
- Alakwaa FM, Gilbert JA. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data. Msystems. 2020;5(2):e00297–20. doi:https://doi.org/10.1128/mSystems.00297-20.
- Zhang TY, Zhong B. Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19. Med Drug Discov. 2020;5:100036. doi:https://doi.org/10.1016/j.medidd.2020.100036.
- Picot S, Marty A, Bienvenu A-L, Blumberg LH, Dupouy-Camet J, Carnevale P, Kano S, Jones MK, Daniel-Ribeiro CT, Mas-Coma S, et al. Coalition: advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health. 2020;9:100131. [published online ahead of print, 2020 Apr 4]. doi:https://doi.org/10.1016/j.onehlt.2020.100131.
- Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787. [published online ahead of print, 2020 Apr 3]. doi:https://doi.org/10.1016/j.antiviral.2020.104787.
- Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? J Am Acad Dermatol. 2020;S0190-9622(20):30557. [published online ahead of print, 2020 Apr 10]. doi:https://doi.org/10.1016/j.jaad.2020.04.017.
- Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. Clin Pharmacol Ther. 2020;108(2):201–11. [published online ahead of print, 2020 Apr 17]. doi:https://doi.org/10.1002/cpt.1857.
- Ford N, Vitoria M, Rangaraj A, Norris SL, Calmy A, Doherty M. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment. J Int AIDS Soc. 2020;23(4):e25489. doi:https://doi.org/10.1002/jia2.25489.
- Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systemic review. J Med Virol. 2020;92(5):479–90. doi:https://doi.org/10.1002/jmv.25707.
- Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turkish J Med Sci. 2020;50(SI–1):611–19. doi:https://doi.org/10.3906/sag-2004-145.
- Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmacother. 2020 May;14:110267. doi:https://doi.org/10.1016/j.biopha.2020.110267.
- Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Lattin BH, Janakiram M, Maziarz RT, McGuirk JP, Nastoupil LJ. CAR T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Trans. 2020;26(7):1239–46. doi:https://doi.org/10.1016/j.bbmt.2020.04.008.
- Zhao RC. Stem Cell-Based Therapy for Coronavirus Disease 2019. Stem Cells Dev. 2020;29(11):679–81. [published online ahead of print, 2020 Apr 17]. doi:https://doi.org/10.1089/scd.2020.0071.
- Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014 Apr 17;508(7496):402–05. doi:https://doi.org/10.1038/nature13027.
- Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012 Jun;86(12):6537–45. doi:https://doi.org/10.1128/JVI.00094-12.
- Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, Wu W, Huang S, Jiang L, Luo X, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020 Mar;29(5):105950. doi:https://doi.org/10.1016/j.ijantimicag.2020.105950.
- Jiang L, Wang N, Zuo T, Shi X, Poon KM, Wu Y, Gao F, Li D, Wang R, Guo J, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med. 2014 Apr 30;6(234):234ra59. doi:https://doi.org/10.1126/scitranslmed.3008140.
- Jawhara S. Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients? Int J Mol Sci. 2020;21(7):E2272. Published 2020 Mar 25. doi:https://doi.org/10.3390/ijms21072272.
- Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus [accessed May 19, 2020]. https://investors.modernatx.com/node/8466/pdf
- Zhu FC, Li YH, Guan XH, Hou L-H, Wang W-J, Li J-X, Wu S-P, Wang B-S, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–54. doi:https://doi.org/10.1016/S0140-6736(20)31208-3.
- Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, Gary EN, Walker SN, Schultheis K, Purwar M, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601. Published 2020 May 20. doi:https://doi.org/10.1038/s41467-020-16505-0.
- Angelidou A, Diray-Arce J, Conti MG, Smolen KK, van Haren SD, Dowling DJ, Husson RN, Levy O. BCG as a case study for precision vaccine development: lessons from vaccine heterogeneity, trained immunity, and immune ontogeny. Front Microbiol. 2020;11:332. Published 2020 Mar 11. doi:https://doi.org/10.3389/fmicb.2020.00332.
- Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet. 2002;359(9308):775–80. doi:https://doi.org/10.1016/s0140-6736(02)07880-7.
- Hooft van Huijsduijnen R, Kojima S, Carter D, Okabe H, Sato A, Akahata W, Wells TNC, Katsuno K. Reassessing therapeutic antibodies for neglected and tropical diseases. PLoS Negl Trop Dis. 2020;14(1):e0007860. Published 2020 Jan 30. doi:https://doi.org/10.1371/journal.pntd.0007860.
- Al Abri S, Kasaeva T, Migliori GB, Goletti D, Zenner D, Denholm J, Al Maani A, Cirillo DM, Schön T, Lillebæk T, et al. Tools to implement the world health organization end TB strategy: addressing common challenges in high and low endemic countries. Int J Infect Dis. 2020;92S:S60–S68. doi:https://doi.org/10.1016/j.ijid.2020.02.042.
- Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, Sadarangani M, Koff W, Kollmann TR. Improving vaccine-induced immunity: can baseline predict outcome? Trends Immunol. 2020;41(6):457-465. doi:https://doi.org/2020;doi:10.1016/j.it.2020.04.001.
- Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173–80. doi:https://doi.org/10.1016/S0140-6736(06)68507-3.
- Sumner T, Scriba TJ, Penn-Nicholson A, Hatherill M, White RG. Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Sci Rep. 2019;9(1):11126. Published 2019 Jul 31. doi:https://doi.org/10.1038/s41598-019-47645-z.
- Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PEM, Rodrigues LC, Smith PG, Lipman M, Whiting PF, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–80. doi:https://doi.org/10.1093/cid/cit790.
- Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne J, Fine P, Smith PG, Lipman M, Elliman D, et al. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. Health Technol Assess. 2013;17(37):1–vi. doi:https://doi.org/10.3310/hta17370.
- Roy P, Vekemans J, Clark A, Sanderson C, Harris RC, White RG. Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study. Lancet Glob Health. 2019;7(12):e1655–e1663. doi:https://doi.org/10.1016/S2214-109X(19)30444-9.
- Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012. doi:https://doi.org/10.1371/journal.pmed.1001012.
- Butkeviciute E, Jones CE, Smith SG. Heterologous effects of infant BCG vaccination: potential mechanisms of immunity. Future Microbiol. 2018;13(10):1193–208. doi:https://doi.org/10.2217/fmb-2018-0026.
- Redelman-Sidi G. Could BCG be used to protect against COVID-19? Nat Rev Urol. 2020:1‐2. doi:https://doi.org/10.1038/s41585-020-0325-9.
- Kumar J, Meena J. Demystifying BCG Vaccine and COVID-19 Relationship. Indian Pediatr. 2020;PII:S097475591600168. [published online ahead of print, 2020 Apr 30]
- Covián C, Fernández-Fierro A, Retamal-Díaz A, Díaz FE, Vasquez AE, Lay MK, Riedel CA, González PA, Bueno SM, Kalergis AM, et al. BCG-induced cross-protection and development of trained immunity: implication for vaccine design. Front Immunol. 2019;10:2806. Published 2019 Nov 29. doi:https://doi.org/10.3389/fimmu.2019.02806.
- Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180–83. doi:https://doi.org/10.1016/S0022-5347(17)58737-6.
- Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol. 2014;11(3):153–62. doi:https://doi.org/10.1038/nrurol.2014.15.
- Alexandroff AB, Jackson AM, O’Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353(9165):1689–94. doi:https://doi.org/10.1016/S0140-6736(98)07422-4.
- Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 2013;104(1):22–27. doi:https://doi.org/10.1111/cas.12075.
- Netea MG, Schlitzer A, Placek K, Joosten LAB, Schultze JL. Innate and adaptive immune memory: an evolutionary continuum in the host’s response to pathogens. Cell Host Microbe. 2019;25(1):13–26. doi:https://doi.org/10.1016/j.chom.2018.12.006.
- Van’t Wout JW, Poell R, van Furth R. The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand J Immunol. 1992;36(5):713–19. doi:https://doi.org/10.1111/j.1365-3083.1992.tb03132.x.
- Andersen P, Kaufmann SHE. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med. 2014;4(6):a018523. doi:https://doi.org/10.1101/cshperspect.a018523.
- Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, et al. Identification of human T cell antigens for the development of vaccines against mycobacterium tuberculosis. J Immunol. 2008;181(11):7948–57. doi:https://doi.org/10.4049/jimmunol.181.11.7948.
- O’Neill LAJ, Netea MG. BCG- induced trained immunity: can it offer protection against COVID-19? Nature Rev. 2020. doi:https://doi.org/10.1038/s41577-020-0337-.
- van Kooyk Y, Engering A, Lekkerkerker AN, Ludwig IS, Geijtenbeek TB. Pathogens use carbohydrates to escape immunity induced by dendritic cells. Curr Opin Immunol. 2004;16(4):488–93. doi:https://doi.org/10.1016/j.coi.2004.05.010.
- Akira S. Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci. 2011;366(1579):2748–55. doi:https://doi.org/10.1098/rstb.2011.0106.
- Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327(5963):291–95. doi:https://doi.org/10.1126/science.1183021.
- Gyssens IC, Netea MG. Heterologous effects of vaccination and trained immunity. Clin Microbiol Infect. 2019;25(12):1457–58. doi:https://doi.org/10.1016/j.cmi.2019.05.024.
- Tanner R, Villarreal-Ramos B, Vordermeier HM, McShane H. The humoral immune response to BCG vaccination. Front Immunol. 2019;10:1317. Published 2019 Jun 11. doi:https://doi.org/10.3389/fimmu.2019.01317.
- Guerra-Maupome M, Vang DX, McGill JL, Basu J. Aerosol vaccination with bacille calmette-guerin induces a trained innate immune phenotype in calves. PLoS One. 2019;14(2):e0212751. Published 2019 Feb 22. doi:https://doi.org/10.1371/journal.pone.0212751.
- Tarancón R, Domínguez-Andrés J, Uranga S, Ferreira AV, Groh LA, Domenech M, González-Camacho F, Riksen NP, Aguilo N, Yuste J, et al. New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathog. 2020;16(4):e1008404. Published 2020 Apr 2. doi:https://doi.org/10.1371/journal.ppat.1008404.
- Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, Dhama K, Yatoo MI, Bonilla-Aldana DK, Rodriguez-Morales AJ, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med. 2020;28(2):174–84.
- Salman S, Salem ML. Routine childhood immunization may protect against COVID-19. Med Hypotheses. 2020;140:109689. doi:https://doi.org/10.1016/j.mehy.2020.109689.
- Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Yan L, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv. 2020. doi:https://doi.org/10.1101/2020.03.24.20042937.
- Iwasaki A, rubau ND. Why does Japan have so few cases of COVID-19? EMBO Mol Med. 2020;12(5):e12481. doi:https://doi.org/10.15252/emmm.202012481.
- Singh BR, Gandharva R. Are BCG vaccination, population density, median age and poverty important determinants of COVID-19 pandemic spread, morbidity and mortality? Researchgate. 2020. doi:https://doi.org/10.13140/RG.2.2.21116.49282.
- Iqbal NT, Hussain R. Non-specific immunity of BCG vaccine: a perspective of BCG immunotherapy. Trials Vaccinol. 2014;3:143–49. doi:https://doi.org/10.1016/j.trivac.2014.08.002.
- Udani PM. BCG vaccination in India and tuberculosis in children: newer facets. Indian J Pediat. 1994;1994(61):451–62. doi:https://doi.org/10.1007/BF02751703.
- Lahariya C. A brief history of vaccines & vaccination in India. Indian J Med Res. 2014;139:491.
- Kuroda N. Demand for BCG vaccine due to unproven claims of its role in preventing COVID-19 is causing shortages of vaccines for infants in Japan. Pediatr Infect Dis J. 2020:Publish Ahead of Print. doi:https://doi.org/10.1097/INF.0000000000002724.
- O’Connor E, The J, Kamat AM, Lawrentschuk N. Bacillus Calmette Gu´erin (BCG) vaccination use in the fight against COVID-19 – what’s old is new again? Future Oncol. 2020;16(19):1323–25. (Epub ahead of print). doi:https://doi.org/10.2217/fon-2020-0381.
- Lawton G. Trials of BCG vaccine will test for covid-19 protection. New Sci. 2020;246(3280):9. doi:https://doi.org/10.1016/S0262-4079(20)30836-8.
- U.S. National Library of Medicine, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04348370